Karng Log, DO
Hematology & Oncology · Littleton, CONPI 1932310034
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,350 of the $3,888 with a category attached, or 60.4%. 37 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 30.5% of the total. Reporting peaked in 2023 at $2,289 and has fallen 83.5% since, to $378 in 2025.
Across 75 payments — averaging $51.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$1K
- Johnson & Johnson$393
- E.r. Squibb & Sons, L.L.C.$344
- Sanofi$207
- Karyopharm Therapeutics Inc.$154
- CTI Biopharma Corp.$149
- plus $1K from 31 others
Across 48 payments — averaging $9158.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$149K
- Astrazeneca UK Limited$103K
- AbbVie$81K
- Merck$80K
- Napo Pharmaceuticals Inc$27K
- Genentech, Inc.$525
What the payments were for
- Consulting fees$1,17030%
- Food & beverage$2,35060%
- Education$3699%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 2 | $1,188 |
| Johnson & Johnson | 6 | $393 |
| E.r. Squibb & Sons, L.L.C. | 6 | $344 |
| Sanofi | 4 | $207 |
| Karyopharm Therapeutics Inc. | 2 | $154 |
| CTI Biopharma Corp. | 2 | $149 |
| Seagen Inc. | 2 | $118 |
| Incyte Corporation | 3 | $116 |
| Tempus AI, Inc | 1 | $108 |
| Amgen | 5 | $97 |
| AstraZeneca | 2 | $94 |
| Sobi, Inc | 2 | $92 |
| Pharmacosmos Therapeutics Inc. | 2 | $70 |
| Argenx US, Inc. | 1 | $56 |
| Novocure Inc. | 2 | $50 |
| Merck | 3 | $49 |
| AbbVie | 2 | $46 |
| Exelixis Inc. | 2 | $46 |
| Pfizer | 2 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Tersera Therapeutics LLC | 2 | $37 |
| Myovant Sciences Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Bristol Myers Squibb | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $27 |
| Mirati Therapeutics, Inc. | 1 | $26 |
| GSK | 1 | $23 |
| Novartis | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| Gilead | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Iovance Biotherapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,888 in reported general payments places this provider in the 60th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 42 | $738,156 |
| IbrancePalbociclib | 38 | $589,836 |
| PromactaEltrombopag Olamine | 29 | $293,452 |
| VerzenioAbemaciclib | 19 | $291,972 |
| PomalystPomalidomide | 11 | $235,780 |
| PiqrayAlpelisib | 11 | $227,210 |
| RevlimidLenalidomide | 23 | $226,008 |
| ZejulaNiraparib Tosylate | 12 | $224,315 |
| CalquenceAcalabrutinib Maleate | 14 | $215,733 |
| SprycelDasatinib | 12 | $213,095 |
| JakafiRuxolitinib Phosphate | 13 | $211,646 |
| XtandiEnzalutamide | 13 | $178,737 |
| TasignaNilotinib Hcl | 14 | $137,601 |
| EliquisApixaban | 62 | $79,973 |
| PegasysPeginterferon Alfa-2a | 15 | $65,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $38 | $738,15642 claims |
| PfizerIbrance, Eliquis, Nyvepria | $43 | $710,390111 claims |
| NovartisPromacta, Piqray, Tasigna | $20 | $658,26354 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $344 | $448,87523 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $20 | $292,25064 claims |
| Bristol Myers SquibbRevlimid | $28 | $226,00823 claims |
| GSKZejula | $23 | $224,31512 claims |
| AstraZenecaCalquence | $94 | $215,73314 claims |
| Incyte CorporationJakafi | $116 | $211,64613 claims |
| Johnson & JohnsonXarelto | $393 | $59,46660 claims |
| AmgenNeupogen | $97 | $47,99317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Littleton
- Manojkumar BupathiLittleton$312K
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.